Skip to content
CancerIndex

Publication

Integrated transcriptomic and functional analyses identify PRR7 as a therapeutic target that associated with Wnt/β-catenin signaling and docetaxel resistance in prostate cancer.

Wei Sun, Yuheng Si, Lu Hong, Qingxiang Guo, Zhihui Lu, Antao Dong, Yurui Tang, Enlai Li, Wei He, Shiyao Feng, Dongdong Xie

Biochemical and biophysical research communicationsSep 24, 2026PMID 42542043doi:10.1016/j.bbrc.2026.154364 Journal ArticlepubmedProvenance
Source
PubMed
Retrieved
Sep 26, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-PUBMED-20260926-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

BACKGROUND: Docetaxel resistance represents a major therapeutic challenge in advanced prostate cancer. Despite extensive studies on drug efflux, apoptosis, and metabolic adaptation, the specific cellular states and molecular determinants that sustain resistance remain poorly understood. METHODS: To…

Read on PubMed

Linked entities

Linked entities (1)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Candidate 1

Curated evidence

Evidence citing this paper (0)

Data not yet available

No curated evidence item cites this publication.